You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
London Health Sciences Center researchers published a study validating the accuracy of the method as a potential screening test for symptomatic male patients.
Researchers from both teams plan to continue to refine their findings toward creating simple PCR or other nucleic acid amplification-based assays.
ISS astronauts will soon begin testing the Oxford Nanopore MinIon and two PCR platforms while researchers on Earth continue to evaluate microarrays for use in space.
The approach can increase CpG coverage about 18-fold by inferring from existing data to predict methylation of sites outside those covered on the arrays themselves.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.